[HTML][HTML] Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer
Y Kiyohara, N Yamazaki, A Kishi - Journal of the American Academy of …, 2013 - Elsevier
Skin toxicities are the most common side effects associated with the epidermal growth factor
receptor inhibitor erlotinib, occurring in most patients receiving the drug. Clinical trials …
receptor inhibitor erlotinib, occurring in most patients receiving the drug. Clinical trials …
[HTML][HTML] Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non-small cell lung cancer
Y Kiyohara, N Yamazaki, A Kishi - Journal of the American Academy of …, 2013 - jaad.org
Skin toxicities are the most common side effects associated with the epidermal growth factor
receptor inhibitor erlotinib, occurring in most patients receiving the drug. Clinical trials …
receptor inhibitor erlotinib, occurring in most patients receiving the drug. Clinical trials …
Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non-small cell lung cancer
Y Kiyohara, N Yamazaki, A Kishi - Journal of the American Academy of …, 2013 - infona.pl
Skin toxicities are the most common side effects associated with the epidermal growth factor
receptor inhibitor erlotinib, occurring in most patients receiving the drug. Clinical trials …
receptor inhibitor erlotinib, occurring in most patients receiving the drug. Clinical trials …
Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
Y Kiyohara, N Yamazaki, A Kishi - Journal of the American Academy …, 2013 - europepmc.org
Skin toxicities are the most common side effects associated with the epidermal growth factor
receptor inhibitor erlotinib, occurring in most patients receiving the drug. Clinical trials …
receptor inhibitor erlotinib, occurring in most patients receiving the drug. Clinical trials …
Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer
Y Kiyohara, N Yamazaki… - Journal of the American …, 2013 - pubmed.ncbi.nlm.nih.gov
Skin toxicities are the most common side effects associated with the epidermal growth factor
receptor inhibitor erlotinib, occurring in most patients receiving the drug. Clinical trials …
receptor inhibitor erlotinib, occurring in most patients receiving the drug. Clinical trials …
[引用][C] Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non-small cell lung cancer
Y Kiyohara, N Yamazaki, A Kishi - Journal of the American Academy of …, 2013 - cir.nii.ac.jp
Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non-small cell
lung cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
lung cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …